Web12 hours ago · Cytokinetics (CYTK) In a report released yesterday, Madhu Kumar from Goldman Sachs maintained a Buy rating on Cytokinetics. The company’s shares closed last Thursday at $35.93, close to its 52 ... WebApr 6, 2024 · Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as …
China Universal Asset Management Co. Ltd. Lowers Holdings in ...
WebFeb 4, 2024 · SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted and filed the ... WebApr 10, 2024 · It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated CYTK. Shares of the company have moved down 20.5% compared with the industry’s decline of 4.7%. cryptoroi
Cytokinetics (Nasdaq:CYTK) - Stock Price, News & Analysis - Simply Wall St
WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 … WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential... WebSTOCK QUOTE Cytokinetics, Inc. INVESTORS & MEDIA STOCK QUOTE Stock Quote Stock Chart Historical Price Lookup Data Provided by Refinitiv. Minimum 15 minutes delayed. Mar 31 2024 11:06 pm EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. STOCK CHART SHAREHOLDER TOOLS cryptorocket coin